A vs LH
A: A diversified healthcare and life sciences company providing analytical instruments, software, and services for pharmaceutical, chemical, and clinical diagnostics laboratories worldwide. LH: Labcorp is a leading global life sciences company providing essential clinical diagnostic testing and drug development services to the healthcare industry.
Side-by-side fundamentals
| Metric | A | LH | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $141.11 | $313.96 | |
| Market cap as of 2026-08-06 | $39.9B | $25.7B | |
| P/E as of 2026-08-06 | 27.94 | 25.34 | LH lower |
| PEG as of 2026-08-06 | 3.55 | 3.11 | LH lower |
| Net margin as of 2026-08-06 | +19.6% | +7.0% | A higher |
| Gross margin as of 2026-08-06 | +52.9% | +28.9% | A higher |
| Operating margin as of 2026-08-06 | +21.5% | +10.4% | A higher |
| ROE as of 2026-08-06 | +20.8% | +11.6% | A higher |
| ROA as of 2026-08-06 | +11.1% | +5.4% | A higher |
| Debt / equity as of 2026-08-06 | 0.47 | 0.69 | A lower |
| Revenue growth (YoY) as of 2026-08-06 | +9.1% | +6.4% | A higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +5.6% | LH higher |
| Dividend yield as of 2026-08-06 | +0.7% | +0.9% | LH higher |
| Dividend streak (yrs) SEC XBRL | 5 | 4 | A higher |
| Beta as of 2026-08-06 | 1.22 | 0.86 | |
| 1-year return as of 2026-08-05 close | +22.8% | +19.2% | A higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.